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Is a compact preﬁlled auto-disable injection
system (cPAD) cost effective for pentavalent
vaccine?
C. Nogier ∗, P. Hanlon, K. Wiedenmayer, N. Maire
Swiss Tropical and Public Health Institute, Basel,
Switzerland
Background: Thepentavalent combinationvaccine is theWHO-
recommended form of the DTP-HepB-Hib vaccine. It is available
in single dose vial (SDV), multi-dose vials (MDV) and soon in a
compact preﬁlled auto-disable injection system (cPAD). A costing
model was developed and used in three countries to perform a
Cost-Effectiveness Analysis (CEA) of these three presentations.
Methods & Materials: The model included the costs of vaccine,
safe injection equipment, storage, transport, distribution, vaccine
administration by health staff, waste management, start-up activi-
ties, coverage andwastage rates. The outcomewas the incremental
cost/savingper fully immunizedchild (FIC) for a switch to cPAD. The
model was used in Peru, Ghana and Cambodia. Field visits to health
facilities, interviews with key informants from immunization ser-
vices and regulatory affairs were conducted.
Results: Based on vaccine price trends estimated for the year
2016, cPAD would be more cost-effective in Ghana compared to
the current presentation (MDV-10) and in Peru (SDV). In Cambodia,
cPAD would be less cost effective (SDV).
The most signiﬁcant driver of the cost per FIC is the cost of the
vaccine (including compensation for vaccine wastage) in any pre-
sentation: accounting for 85% of total cost in Peru and over 97% in
the two other countries. The dominance of the vaccine price per
dose and to a lesser extent the wastage rates and cost of safe injec-
tion equipment as drivers of the incremental cost per FIC show
the potential to simplify future analyses. Programmatic contexts
and perceptions of stakeholders inﬂuence the decision to introduce
new vaccine presentations. Other factors include the potential for
improved safetywith cPAD, planned introduction of other vaccines
and environmental issues relating to reduced waste generation.
Conclusion: Based on vaccine price estimated for the year 2016,
the cPAD could be the most cost-effective presentation in many
countries. For decision making and policy dialogue other factors
(injection safety, programmatic aspects, etc.) may be important
when considering shifting to a new vaccine presentation such as
cPAD.
Conﬂict of interest: Crucell funded the study.
Table 1.
Table 1
Incremental costs of cPAD as compared to the current pentavalent presentation
Cambodia,
2013-2020
Ghana,
2013-2017
Peru, 2013-2017
Incremental cost per FIC
USD (%)
0.32 (+3.76%) −0.58 (-6.41%) −0.90 (-7.20%)
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Clinical development of a recombinant live
attenuated tetravalent dengue vaccine
J. Osorio
Takeda vaccines, Madison, USA
Background: Takeda is developinga tetravalent, live attenuated
dengue vaccine (LADV) consisting of a molecularly characterized,
attenuatedDENV-2 strain and three chimeras inwhich the prMand
E genes of the attenuated DENV-2 were substituted with those of
DENV- 1, -3 or -4 viruses.
Methods & Materials: Takeda is conducting Phase 1 and 2 clin-
ical trials for the LADV
Results: The results of our Phase 1 and 2 clinical trials in healthy
subjects support the safety and immunogenicity of the tetravalent
vaccine. Administration of LADV was generally well-tolerated with
mostly mild and transient local or systemic reactions. There were
no related serious or severe adverse events (AEs), and no discontin-
uations due to vaccine-related AEs. The LADV induced neutralizing
antibody responses to all four dengue viruses after one or two
administrations.
Conclusion: These studies highlight the safety and immuno-
genicity of the tetravalent LADV vaccine in children and adults in
dengue endemic countries. Based on our results from Phase 1 and
2 studies, the LADV warrants further evaluation in Phase 3 efﬁcacy
studies in children and adults in dengue-endemic countries.
http://dx.doi.org/10.1016/j.ijid.2014.03.1324
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A large single-center retrospective analysis of
neutralizing antibodies after intradermal
pre-exposure rabies vaccination
P. Geeraerts1, A. Collee1, P. Soentjens2,∗
1 Division Health, Well Being, Brussels, Belgium
2 Centre for Infectious Diseases, Brussels, Belgium
Background: Soldiers in the Belgian Defence are intradermally
vaccinated for rabies pre-deployment since 2008 by a four injec-
tion schedule (day 0,7, 28, 365). Neutralizing antibody titers against
rabieswere tested7days after booster vaccination. Serology results
of subjects, vaccinated between the 1st of april 2008 and the 31st
of june 2013, were evaluated. A titer of the Rapid Fluorescent Focus
Inhibition Test (RFFIT) ≥ 0,5 IU/ml is considered to be boostable. A
titer >3,0 IU/ml is considered to give sufﬁcient protection and>10
IU/ml a long-lasting immunity.
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Methods & Materials: Soldiers in the Belgian Defence are intra-
dermally vaccinated for rabies pre-deployment since 2008by a four
injection schedule (day 0,7, 28, 365). Neutralizing antibody titers
against rabies were tested 7 days after booster vaccination. Sero-
logy results of subjects, vaccinated between the 1st of april 2008
and the 31st of june 2013, were evaluated. A titer of the Rapid Flu-
orescent Focus Inhibition Test (RFFIT) ≥ 0,5 IU/ml is considered
to be boostable. A titer > 3,0 IU/ml is considered to give sufﬁcient
protection and>10 IU/ml a long-lasting immunity.
Results: 6598 subjects started pre-exposure rabies vaccination
in the Belgian Army in these period. 1658 subjects were excluded
due to lack of certainty of intradermal injection method 4940 sub-
jects started intradermal rabies vaccination 4285 ﬁnished initial
vaccination (d0, 7, 28) 1363 had a fourth vaccination (booster) 881
had a serology test (RFFIT) done after booster vaccination Median
age was 36.4 year (with a standard deviation of 9,2), Gender was in
96.1% male. Neutralizing Antibodies were as follows: - 100% (881)
of subjects had RFFIT above 0,5 IU/ml; - 83,3% (734) of subjects had
a long-lasting immunity whit RFFIT above 10 IU/ml; - 96.6% (851)
of subjects had a RFFIT above 3.0 IU/ml. We observed a delay in
days of serology testing (mean=145 (SD 6,3/range 7–1603).
Conclusion: The Classical (day 0, 7, 28, 365) Intradermal Pre-
exposureVaccination is Immunogenic andVery Promising to tackle
the problem of Volume Shortage in Biologicals worldwide. Neu-
tralizing Antibodies after four intradermal rabies injections are
considered to be boostable in 100% of cases and protective in 96,6%
of subjects in this largest cohort of intradermal vaccination world-
wide.
http://dx.doi.org/10.1016/j.ijid.2014.03.1325
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Progress towards elimination of rubella and
congenital rubella syndrome in Singapore: Are
we there yet?
Y. X. Chua1,∗, L. W. Ang2
1 National University Health System, Singapore,
Singapore
2 Ministry of Health, Singapore, Singapore, Singapore
Background: Singapore has a comprehensive national child-
hood immunization programme which includes rubella. The
objectives of this study were to describe the epidemiology of
rubella in Singapore from 2003 to 2012, and assess its progress
in implementing key control strategies against the disease, mea-
sured against the targets set by the World Health Organization
(WHO) Western Paciﬁc Regional Ofﬁce (WPRO) of reducing rubella
and congenital rubella syndrome (CRS) incidence to below 10
indigenous cases per million population and 10 cases per million
live-births, respectively, by 2015.
Methods & Materials: Epidemiological data on all suspected
and laboratory-conﬁrmed rubella cases notiﬁed to the Ministry of
Health for the period 2003-2012 were used. Data on vaccination
coverage was obtained from the National Immunization Registry.
To assess population immunity against rubella, two National Sero-
prevalence Surveys (NSS) were conducted based on residual blood
samplesof adult residents fromtheNationalHealthSurveys in2004
and 2010.
Results: The incidence of rubella ranged from12–37 permillion
population during the 10-year period. The age-speciﬁc incidence
rate of rubella was the highest in children below 5 years of age.
The incidence of indigenous cases decreased from 36.2 in 2008 to
10.7 per million population in 2012. The susceptibility to rubella
in women aged18-44 years decreased signiﬁcantly from 15.8% in
2004 to 11.0% in 2010 (p=0.001). Non-residents constituted 51%
of the cases notiﬁed among women in this reproductive age group.
There were nine cases of CRS reported during this period, and over
66% were imported cases. In the past decade, the annual vaccina-
tion coverage against measles, mumps and rubella (MMR) among
Singapore residents at 2 years of age and students aged 11-12 years
had been maintained between 93% and 96%. For school entrants
aged 6-7 years and those aged 11 years, the annual coverage rate
was between 92% and 95% from 2008 to 2012.
Conclusion: Singapore has made progress and is on track
towards elimination of rubella and CRS. The NCIP has been suc-
cessful in increasing the population immunity against rubella and
preventing CRS through concerted efforts. The current high vacci-
nation coverage and vigilant case surveillance should be sustained.
http://dx.doi.org/10.1016/j.ijid.2014.03.1326
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Synthetic hexasaccharide of the capsular
polysaccharide of S. pneumoniae type 14
induces cytokines
E. Akhmatov1,∗, E. Kurbatova1, N. Akhmatova1, E.
Sukhova2, D. Yashunsky2, Y. Tsvetkov2, N.
Nifantiev2
1 Mechnikov Research Institute of Vaccines and Sera,
Moscow, Russian Federation
2 N. D. Zelinsky Institute of Organic Chemistry,
Moscow, Russian Federation
Background: Cytokines play a crucial role in immune response.
The inﬂuence of synthetic oligosaccharides on the cytokine produc-
tion is not completely investigated. Aim. The study of the cytokine
production in mice in response to a conjugate of a synthetic hexas-
accharide fragment of the capsular polysaccharide of S.pneumoniae
type 14 and BSA as a model protein carrier.
Methods & Materials: The hexasaccharide-BSA conjugate (HC)
was prepared by the squarate method and contained, according
to the MALDI-TOF data, 18 hexasaccharide residues on average.
Sera from mice after immunization with HC were tested in ﬂow
cytometry using test system FlowCytomixMouse Thl/Th2 10plex
(BenderMedSystems). The subisotypes of IgG were determined in
ELISA using HC as a well-coating antigen. The protective activity
of HC was evaluated by challenge of the immunized mice with S.
pneumoniae type 14.
Results: Intraperitoneal injection of HC adsorbed on alum
hydroxide in CBA mice led to appearance of IL-1, IL-5, IL-6, IL-10,
IL-17, TNF, GM-CSF that increased in 2hours and remained at the
same level within 24hours as compared with control mice. Bichro-
matic increase in concentration of IFN began to rise later - 4h after
